Mode
Text Size
Log in / Sign up

Hepatitis C

Part of Hepatitis

24 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hepatitis C

319 trials tracked for Hepatitis C: 128 in phase 3 or 4 and 55 with published results. The most-cited published study has 1128 citations.

319Trials tracked
128Phase 3 & 4
0Recruiting
55With published results
Phase distribution
Phase 4 32 Phase 3 96 Phase 2 98 Phase 1 29 Other / NA 64
  1. Phase 4 Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs Completed · 1,128 cited
  2. Phase 3 Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection Completed · 1,123 cited
  3. Phase 3 Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection Completed · 859 cited
  4. Phase 3 Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection Completed · 858 cited
  5. Phase 3 Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis Completed · 812 cited
  6. Phase 3 Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052) Completed · 673 cited
Show 44 more trials
  1. Phase 3 Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy Completed · 571 cited
  2. Phase 3 Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor Completed · 571 cited
  3. Phase 3 Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection Completed · 471 cited
  4. Phase 4 Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care Completed · 314 cited
  5. Phase 3 A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection Completed · 305 cited
  6. Phase 4 Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients Completed · 298 cited
  7. Phase 3 Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease Completed · 279 cited
  8. Phase 3 Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis Completed · 240 cited
  9. Phase 3 Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy Completed · 239 cited
  10. Phase 3 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection Completed · 232 cited
  11. Phase 3 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy Completed · 203 cited
  12. Phase 3 Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis Completed · 189 cited
  13. Phase 3 A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2) Completed · 185 cited
  14. Phase 3 Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection Completed · 161 cited
  15. Phase 3 Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir Completed · 153 cited
  16. Phase 3 A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) Completed · 148 cited
  17. Phase 3 Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV Completed · 121 cited
  18. Phase 3 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection Completed · 119 cited
  19. Phase 3 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection Completed · 113 cited
  20. Phase 3 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection Completed · 113 cited
  21. Phase 4 Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection Completed · 112 cited
  22. Phase 3 Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058) Completed · 77 cited
  23. Phase 3 Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065) Completed · 75 cited
  24. Phase 3 Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study Completed · 74 cited
  25. Phase 3 Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077) Completed · 54 cited
  26. Phase 3 A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1) Completed · 53 cited
  27. Phase 3 Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection. Completed · 51 cited
  28. Phase 4 Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors Completed · 50 cited
  29. Phase 3 A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults Completed · 50 cited
  30. Phase 3 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection Completed · 49 cited
  31. Phase 3 Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067) Completed · 46 cited
  32. Phase 4 Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds Completed · 43 cited
  33. Phase 3 Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects Completed · 43 cited
  34. Phase 3 Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV Completed · 43 cited
  35. Phase 3 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection Completed · 40 cited
  36. Phase 3 A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection Completed · 40 cited
  37. Phase 3 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis Completed · 40 cited
  38. Phase 3 The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4) Completed · 40 cited
  39. Phase 4 Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection Completed · 34 cited
  40. Phase 4 Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis Completed · 27 cited
  41. Phase 4 Multi-center Study to Transplant Hepatitis-C Infected Kidneys Completed · 20 cited
  42. Phase 3 Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection Completed · 15 cited
  43. Phase 3 Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis Completed · 15 cited
  44. Phase 3 Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection Completed · 15 cited

Showing the 50 most-cited and recently-updated of 319 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Hepatitis C: what the trials found

Sofosbuvir-based regimens demonstrate high efficacy in treating Hepatitis C. Specifically, sofosbuvir/velpatasvir (SOF/VEL) achieved a 95% SVR12 rate with low rates of serious adverse events (3.5%) and unplanned clinic visits (3.8%) 6. Other trials confirmed the use of sofosbuvir/velpatasvir in various settings, including post-transplant contexts where it showed specific outcomes regarding allograft rejection and graft loss 1, as well as general treatment cohorts [16, 17].

Alternative regimens such as glecaprevir/pibrentasvir demonstrated high viral response rates at 2 and 4 weeks with no Grade 3 or higher treatment-related adverse events reported 20. Additionally, glecaprevir/pibrentasir showed a 12% on-treatment virologic failure rate but 0% post-treatment virologic relapse 11.

The use of Zepatier (elbasvir/grazoprevir) was evaluated across multiple studies; it showed no Grade 3 or higher treatment-related adverse events and stable kidney function at 6 and 12 months [5, 13, 15]. Other combinations including elbasvir/grazoprevir were also utilized in post-transplant settings 14 and as EBR/GZR 21.

Harvoni (ledipasvir/sofosbuvir) was associated with a statistically significant reduction in liver fibrosis 19, and significantly higher rates of ALT normalization compared to other sofosbuvir-based DAA therapies 19. Other interventions included ribavirin 9, antiretroviral therapy (ART) 8, and TDF with a boosted protease inhibitor, the latter of which showed specific changes in PBMC levels and renal biomarkers 18.

Recent results — preliminary, needs further review

  • Mobile Enhanced Prevention Support significantly increased the number of participants who initiated a PrEP regimen compared to those who did not (p=0.0006) 2.
  • Maraviroc showed no significant change in Hepatitis C viral load at 4 weeks or 7 days post-initiation 12.

For the clinician treating this condition

  • Sofosbuvir/velpatasvir is a highly effective treatment with high SVR12 rates and manageable safety profiles [6, 16, 17].
  • Harvoni (ledipasvir/sofosbuvir) is associated with significant improvements in liver fibrosis and ALT normalization 19.
  • Glecaprevir/pibrentasvir shows high early viral response rates and favorable safety profiles [11, 20].
  • Zepatier (elbasvir/grazoprevir) demonstrates a favorable safety profile regarding renal function and severe adverse events [5, 13, 15].

AI synthesis of 12 cited trials, updated Jun 23, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Hepatitis

Related studies from across the Hepatitis family.

Peg-interferon add-on to nucleoside analogues achieves HBsAg loss in 8.6% of patients
Infectious Disease Meta-analysis
Peg-interferon add-on to nucleoside analogues achieves HBsAg loss in 8.6% of patients Adding peg-interferon to standard treatment helps some hepatitis B patients
This meta-analysis of 581 patients with chronic hepatitis B evaluates peg-interferon add-on to nucleoside analogue therapy. The analysis fou…
Adding peg-interferon to standard nucleoside therapy can help some patients with chronic hepatitis B achieve a key milestone in their treatm…
TZ84-based hepatitis A vaccine shows higher seroconversion rates and GMCs than HM175-based vaccine
Gastroenterology Meta-analysis
TZ84-based hepatitis A vaccine shows higher seroconversion rates and GMCs than HM175-based vaccine TZ84 vaccine shows stronger long-term protection against hepatitis A
This meta-analysis of 3,282 children and adolescents found that the TZ84-based hepatitis A vaccine is associated with higher seroconversion …
One type of hepatitis A vaccine shows higher antibody levels and longer protection in children compared to another common vaccine type.
HBsAg prevalence 9.98% in Cameroon, higher-risk groups 12.70%
Gastroenterology Meta-analysis
HBsAg prevalence 9.98% in Cameroon, higher-risk groups 12.70% New data reveals high rates of Hepatitis B in Cameroon
This meta-analysis of 100 studies estimates HBsAg prevalence at 9.98% in Cameroon, with lower-risk populations at 8.94% and higher-risk at 1…
Nearly 10 percent of people in Cameroon test positive for Hepatitis B, with higher rates found in certain high-risk groups.
Immune markers correlate with clinical outcomes following nucleos(t)ide analogue withdrawal in chronic hepatitis B
Gastroenterology Sys. Review
Immune markers correlate with clinical outcomes following nucleos(t)ide analogue withdrawal in chronic hepatitis B Immune Markers May Predict Outcomes After Hepatitis B Treatment
This mini review synthesizes immune correlates of outcome after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B. Bene…
New research identifies specific immune markers that may help predict how patients respond when stopping nucleoside analogue medications for…
Bidirectional virus-metabolism interaction in chronic hepatitis B and metabolic dysfunction-associated fatty liver disease
Allergy & Immunology Sys. Review
Bidirectional virus-metabolism interaction in chronic hepatitis B and metabolic dysfunction-associated fatty liver disease Liver disease and hepatitis B may fuel each other
This systematic review examines the interplay between viral infection and metabolic factors in patients with chronic hepatitis B and metabol…
Hepatitis B and fatty liver disease may worsen each other, raising liver cancer risk. New review explains the link.
Elevated serum M2BPGi is associated with a 4.61 hazard ratio for hepatocellular carcinoma development
Rheumatology Meta-analysis
Elevated serum M2BPGi is associated with a 4.61 hazard ratio for hepatocellular carcinoma development Elevated M2BPGi Levels Linked to Higher Risk of Liver Cancer
This systematic review and meta-analysis of 12,161 participants found that elevated serum M2BPGi is significantly associated with an increas…
A large review of over 12,000 patients found that high levels of a specific protein may signal an increased risk for liver cancer.
Dolutegravir and lamivudine achieved 78% HIV-1 RNA suppression in patients with isolated reactive anti-HBc
Infectious Disease RCT
Dolutegravir and lamivudine achieved 78% HIV-1 RNA suppression in patients with isolated reactive anti-HBc Trial shows dolutegravir and lamivudine are safe for patients with HIV
This pooled analysis of Phase 3/3b trials evaluated dolutegravir/lamivudine (DTG/3TC) in adults with HIV-1 and isolated reactive hepatitis B…
A review of multiple trials shows that a common two-drug regimen effectively manages HIV while remaining safe for those with hepatitis B ant…
Susceptibility-guided combination therapy improves neurological status and reduces abscess size in a patient with nocardiosis
Hematology Meta-analysis
Susceptibility-guided combination therapy improves neurological status and reduces abscess size in a patient with nocardiosis Case report: Brain infection in autoimmune hepatitis patient
This case report describes the management of disseminated nocardiosis in a 55-year-old man with autoimmune hepatitis. The patient showed gra…
A man with autoimmune hepatitis developed a rare brain infection after immunosuppression. Doctors treated it successfully with targeted anti…
JAK inhibitors are associated with higher hepatitis B virus reactivation rates than IL-12/23 or IL-17 inhibitors
Gastroenterology Meta-analysis
JAK inhibitors are associated with higher hepatitis B virus reactivation rates than IL-12/23 or IL-17 inhibitors Specific Immune Inhibitors Show Varying Risks for Hepatitis B Reactivation
This meta-analysis of 29 studies evaluated the risk of hepatitis B virus reactivation (HBVr) in patients receiving various immunomodulators.…
New analysis shows that certain immune inhibitors like JAK inhibitors may carry a higher risk of hepatitis B reactivation than other drug cl…
HBeAg seroclearance in HBeAg-positive chronic hepatitis B correlates with disease remission and reduced hepatocellular carcinoma risk
Infectious Disease Sys. Review
HBeAg seroclearance in HBeAg-positive chronic hepatitis B correlates with disease remission and reduced hepatocellular carcinoma risk Clearing HBeAg helps manage chronic hepatitis B and liver risk
This systematic review examines the clinical significance and optimization strategies of HBeAg seroclearance in patients with HBeAg-positive…
Achieving HBeAg seroclearance in patients with chronic hepatitis B can lead to disease remission and a lower risk of developing liver cancer…
Autoimmune hepatitis pathogenesis shifts from single molecule to immune-metabolic network analysis
Drug Pipeline Sys. Review
Autoimmune hepatitis pathogenesis shifts from single molecule to immune-metabolic network analysis New Research Maps Complex Networks in Autoimmune Hepatitis
This systematic review reframes autoimmune hepatitis (AIH) pathogenesis from a single-molecule perspective to a systematic regulatory networ…
Researchers are moving beyond single-molecule views to map complex immune and metabolic networks that drive autoimmune hepatitis.
Evaluating the Impact of Digital Health Interventions on Chronic Disease Self-Care Outcomes
Physical Medicine & Rehab Meta-analysis
Evaluating the Impact of Digital Health Interventions on Chronic Disease Self-Care Outcomes Digital health tools show mixed results for managing chronic diseases
Digital tools show promise for heart failure monitoring but lack consistent evidence for improving medication adherence or general diabetes …
New data shows that while digital tools like apps can help heart failure patients monitor their health, they may not improve medication habi…

Questions about Hepatitis C

How should healthcare workers follow up after an acute Hepatitis C Virus infection?

Healthcare workers with acute HCV should undergo baseline and serial HCV RNA testing, with follow-up for at least 6 months to confirm clearance or initiate treatment.

Full answer →
Why is the CDC recommending universal screening for Hepatitis C for pregnant women?

The CDC recommends universal Hepatitis C screening for all pregnant women because infection rates have doubled in the US since 2009, many cases go undiagnosed, and screening is now considered cost-effective.

Full answer →
Does taking ribavirin for Hepatitis C cause more genetic mutations in the virus?

Yes, ribavirin increases genetic mutations in HCV, as shown by a randomized trial that found higher mutational load and specific nucleotide changes in the virus.

Full answer →
How has the rate of Hepatitis C changed among younger adults in the US?

Hepatitis C rates have increased dramatically among younger US adults, driven by the opioid epidemic and injection drug use.

Full answer →

All Hepatitis C Articles